biostudies-literatureShah BDNCI NIH HHS491-502https://www.ebi.ac.uk/biostudies/studies/S-EPMC11613962biostudies-literatureUnknown398(10299)<h4>Background</h4>Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies.<h4>Methods</h4>We report the pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study evaluating the efficacy and safety of the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Patients were enrolled at 25 sites in the USA, Canada, and Europe. Eligible patients were aged 18 years or older, with Eastern Cooperative Oncology Group performance status of 0-1, and morLancet (London, England)KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.PMC11613962P30 CA016672Schiller GJTzachanis DMinnema MCLin YHouot RDeAngelo DJFeng CDong JTopp MSAbedi MShen TJeyakumar DBaer MRMasouleh BKRossi JMLeguay TPark JHShah BDBoissel NLogan ACSubklewe MO'Dwyer KMOluwole OOStiff PGhobadi ACassaday RDBishop MRWierda WGMilletti FVezan RArellano MLfalseKTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.<h4>Background</h4>Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies.<h4>Methods</h4>We report the pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study evaluating the efficacy and safety of the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Patients were enrolled at 25 sites in the USA, Canada, and Europe. Eligible patients were aged 18 years or older, with Eastern Cooperative Oncology Group performance status of 0-1, and mor2021-01-01T00:00:00Z2021 Aug2026-06-03T00:58:02.201Z2025-04-06T22:27:11.88ZS-EPMC116139623409785210.1016/s0140-6736(21)01222-810.1016/S0140-6736(21)01222-8